Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide,

Similar presentations


Presentation on theme: "A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide,"— Presentation transcript:

1 A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide, and Antithymocyte Globulin for Chronic Granulomatous Disease  Pooja Khandelwal, Jacob J. Bleesing, Stella M. Davies, Rebecca A. Marsh  Biology of Blood and Marrow Transplantation  Volume 22, Issue 11, Pages (November 2016) DOI: /j.bbmt Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Neutrophil oxidative burst by 123 dihydrorhodamine in 4 patients who received RIC regimens at last follow-up. Patients 1 and 4 demonstrate a normal study, whereas patients 2 and 3 demonstrate 2 populations of neutrophils, consistent with their mixed donor chimerism. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 (A) Whole blood donor chimerism at engraftment, the lowest chimerism before any interventions (withdrawal of immune suppression, DLI, or CD34+ selected stem cell infusion), the highest chimerism after any or all interventions, and the chimerism at last follow-up for all 4 patients who received a RIC regimen (RIC patients 1, 2, 3, and 4) and 14 patients who received the MAC regimen (MAC 1; MAC 2 to 14 represented together). (B) Neutrophil oxidative burst after engraftment, the lowest oxidative burst before any interventions (withdrawal of immune suppression, DLI, or CD34+ selected stem cell infusion), the highest oxidative burst after any or all interventions, and the oxidative burst at last follow-up for all 4 patients who received a RIC regimen (RIC patients 1, 2, 3, and 4) and 14 patients who received the MAC regimen (MAC 1; MAC 2 to 14 represented together). Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions


Download ppt "A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide,"

Similar presentations


Ads by Google